Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
acute myeloid leukemia (AML)
cellular therapy
hematopoietic stem cell transplantation (HSCT)
hypometylating agents
maintenance therapy post-HSCT in AML
targeted drugs
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
11
09
2024
revised:
05
10
2024
accepted:
08
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option for eligible patients. Relapse after HSCT is a dramatic event with poor chances of survival. With the aim of reducing the rate of post-HSCT relapse, maintenance treatment has been investigated in this setting. Results from clinical trials suggest an advantage in the use of a maintenance strategy; however, standardized guidelines are not yet available due to the lack of prospective clinical trials. In this review, we have reported the most important strategies adopted as post-HSCT maintenance, highlighting their efficacy, but the current research also opens questions.
Identifiants
pubmed: 39451755
pii: curroncol31100451
doi: 10.3390/curroncol31100451
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM